CoChat

Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy

Open access

Published version of a preprint

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 15 of the 29 sources its claims cite were checked for support.

Abstract

SagA promotes immunotherapy response: The gut microbiome can influence the treatment outcome for cancer patients receiving PD-L1 immunotherapy, but the mechanisms underlying favorable responses are unclear. Griffin et al . found that a particular type of bacteria called enterococci enhance anti–PD-L1 immunotherapy in mice (see the Perspective by Ansaldo and Belkaid). The researchers show that enterococci secrete an enzyme called SagA that breaks down components of the bacterial cell wall. This process results in the release of muramyl peptide fragments, which in turn act as stimulatory molecules to promote signaling of the innate immune sensor protein NOD2 and improved immunotherapy responses. —PNK

Overview

CoChat Summary

TL;DR

Enterococcus species that produce secreted NlpC/p60 peptidoglycan hydrolases (SagA orthologs) improve checkpoint inhibitor responses in mouse tumor models by generating NOD2-active muropeptides. Engineering SagA into non-active E. faecalis or probiotic L. lactis, or giving synthetic MDP-l,d, reproduced antitumor benefit with anti-PD-L1.

Key findings

  • In antibiotic-pretreated C57BL/6 mice bearing B16-F10 melanoma, oral E. faecium Com15 plus anti-PD-L1 reduced tumor size at high and low antibody doses versus anti-PD-L1 alone; all three E. faecium isolates tested were active, while no E. faecalis strain was. Similar fecal CFU across strains indicated the effect was not due to bacterial load.
  • Active species E. durans, E. hirae, and E. mundtii shared peptidoglycan remodeling signatures and SagA orthologs; C-terminal NlpC/p60 domains were >90% identical, E. gallinarum’s closest protein was 67% identical, and E. faecalis lacked direct orthologs. Recombinant orthologs showed d,l-endopeptidase activity producing GMDP.
  • E. faecalis engineered to express SagA plus anti-PD-L1 reduced B16-F10 growth, and this required NOD2. L. lactis expressing wild-type SagA matched E. faecium benefit, whereas catalytically inactive C443A SagA did not.
  • Synthetic NOD2-active MDP-l,d with anti-PD-L1 significantly inhibited tumors, unlike MDP-l,l; scRNA-seq showed more intratumoral T lymphocytes, cytotoxic gene enrichment, a Cx3cr1/Nr4a1 monocyte increase, and NF-κB/inflammatory signatures.

Methods

  • Mouse tumor models: SPF C57BL/6 mice (Jackson) pretreated two weeks with ampicillin, colistin, and streptomycin, then orally supplemented with enterococci, implanted with B16-F10 melanoma and treated with anti-PD-L1; separate Taconic SPF mice without antibiotics; MCA205 fibrosarcoma with anti-PD-1 and MC38 colorectal carcinoma with anti-CTLA-4; B16-OVA for flow cytometry.
  • Bacterial and biochemical assays: HPLC-MS peptidoglycan fragment profiling, genomic/sequence alignments for SagA orthologs, Western blot for secretion, recombinant hydrolase activity assays, fecal/tissue CFU, and 16S rRNA microbiome analysis.
  • Immune profiling: tumor-infiltrating lymphocytes quantified by flow cytometry; CD45+ tumor cells from MDP stereoisomer-treated mice analyzed by scRNA-seq and gene set enrichment.

Limitations

  • Stated: the authors could not detect SagA orthologs in clinical metagenomic datasets before checkpoint blockade, which they attribute to low E. faecium genome coverage (9.34%). They also note uncertainty for the secretion-deficient L. lactis SagA strain, suggesting either low secreted SagA was sufficient or non-secreted SagA leaked via lysis.
  • Evident: efficacy and mechanism data come from mouse tumor models and bacterial/muropeptide interventions, not human clinical trials; antibiotic pretreatment substantially depletes resident microbiota, although a non-antibiotic SPF model was also used.
  • Evident: microbiome analyses showed incomplete antibiotic clearance and shifts over time, and some differential OTUs appeared in only one cage per condition, limiting microbiome attribution.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/science.abc9113

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

8 Valid · 0 Not valid · 7 Not checked · 63 Own results and interpretations

54 more claims

Create a free account to see all 78 claims and to verify the 14 references still open.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 14

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 367

Metadata

Authors
Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C.
Affiliations
  • Scripps Research Institute (US)
  • Rockefeller University (US)
  • Rise Therapeutics, 1405 Research Blvd. Suite 220, Rockville, MD 20850, USA.
Corresponding author
Hang, Howard C.
Venue
Science
Published
2021-08-27
Volume
373
Issue
6558
Pages
1040-1046
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3194929095
Cited by
366
References
75
Citations by year
2026: 69 · 2025: 71 · 2024: 83 · 2023: 80 · 2022: 52 · 2021: 10
FWCI
20.67
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Science (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (1R01CA245292-01, A1070084)
  • Melanoma Research Foundation (Career Development Award)
  • ASCRS Research Foundation (HCFR-19-03-02)
  • Hope Funds for Cancer Research (HCFR-19-03-02)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
Enterococcus, sagas, peptidoglycan remodeling, cancer immunotherapy, PD-L1 blockade, gut microbiota, muramyl peptides, NOD2 signaling, innate immunity, bacterial cell wall degradation
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Bacterial Proteins, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, N-Acetylmuramoyl-L-alanine Amidase, Peptide Fragments, Peptidoglycan, Enterococcus faecalis, Signal Transduction, Enterococcus, Enterococcus faecium, Probiotics, Mice, Nod2 Signaling Adaptor Protein, Bacterial Load, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.